BioNTech (NASDAQ:BNTX – Get Free Report) had its price objective decreased by equities research analysts at HC Wainwright from $130.00 to $110.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s target price would suggest a potential upside of 26.13% from the stock’s previous close.
BNTX has been the subject of several other reports. Canaccord Genuity Group decreased their price objective on shares of BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. Wall Street Zen raised shares of BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and cut their target price for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research report on Friday, October 2nd. Finally, Bank of America reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $122.27.
View Our Latest Stock Report on BNTX
BioNTech Stock Down 0.3%
Insider Buying and Selling at BioNTech
In related news, CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the sale, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 807,209 shares of company stock valued at $79,246,837. 19.20% of the stock is currently owned by insiders.
Institutional Trading of BioNTech
Institutional investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC bought a new position in shares of BioNTech in the 2nd quarter worth about $2,520,000. Bank of America Corp DE boosted its holdings in shares of BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after buying an additional 166,432 shares during the period. Amundi boosted its holdings in shares of BioNTech by 24.5% in the 1st quarter. Amundi now owns 129,513 shares of the company’s stock valued at $11,511,000 after buying an additional 25,506 shares during the period. Assenagon Asset Management S.A. grew its position in shares of BioNTech by 79.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock valued at $74,774,000 after buying an additional 337,412 shares during the last quarter. Finally, Flossbach Von Storch SE bought a new stake in shares of BioNTech during the 2nd quarter valued at about $207,142,000. Institutional investors own 15.52% of the company’s stock.
About BioNTech
BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.
Further Reading
- Five stocks we like better than BioNTech
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
